APR 21, 2015 11:21 AM PDT

New Drug Combination Shows Promise for Breaking Breast Cancer Resistance

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
In the most common type of breast cancer, affecting 70 percent of patients, the drug Sulforadex helps overcome resistance to routinely used hormonal treatments by targeting the cancer stem cell population.
In research revealed at the American Association of Cancer Research annual conference on Monday, the researchers show that in the most common type of breast cancer, affecting 70 percent of patients, the drug Sulforadex helps overcome resistance to routinely used hormonal treatments by targeting the cancer stem cell population.

While most women initially respond well to hormonal treatment with drugs such as tamoxifen, many go on to develop resistance and relapse. There is evidence that this is often due to activation of the Wnt signalling pathway, a gene involved in development which fuels the growth of the tumor.

Around 70 percent of breast cancers express the ‘estrogen receptor' (ER) and typical treatment focuses on reducing estrogen levels or blocking ER function. However, the researchers have shown that cancer stem cells which cause tumors to regrow and spread do not express the ER. Thus, these stem cells aren't inhibited by the standard treatments and have the ability to regrow the tumor.

The new combination therapy, tested in lab studies by the Manchester scientists, combines Evgen's Wnt pathway-suppressing drug, Sulforadex with standard hormonal treatments. This targets both the estrogen-sensitive cells and the remaining cancer stem cells at the same time.

Dr Robert Clarke from the University's Institute of Cancer Sciences said: "The hormonal therapies we use today are very good at treating breast cancer tumors driven by estrogen.
"However, they don't completely solve the problem. This combination of drugs potentially allows us to target estrogen-sensitive cells, whilst also mopping up the cells which cause treatment resistance."

The study was carried out in lab samples of treatment resistant cells from breast cancer patients. The next step will be to recruit patients for a trial in the next few months.

Dr David Howat, Head of Research and Development at Evgen Pharma said: "We are really excited about the data presented at the AACR. Dr Rob Clarke and his excellent research team have demonstrated the efficacy of Sulforadex in patient derived cancer tissues in vitro and, importantly, in an in vivo setting.

"We now intend to extend this collaboration and advance Sulforadex into a clinical trial with breast cancer patients."

Source: University of Manchester
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 14, 2019
Cancer
OCT 14, 2019
An Ointment to Stop Skin Cancer Growth
Russian scientists are developing an ointment to undermine the growth of skin cancer, according to a review recently published in Molecules. One in three c...
OCT 14, 2019
Cancer
OCT 14, 2019
Don't Combine Breast and Gyno Surgery, Study Advises
Surgeries can be stressful and difficult for patients, and it’s understandable that some would want to reduce the number of days they need to devote...
OCT 14, 2019
Health & Medicine
OCT 14, 2019
Does Cuttlefish Ink Hold a Cure for Cancer?
Using nanoparticles to deliver cancer-fighting compounds directly into tumors has been a hot research topic for the past few years. According to Lisa Ayga...
OCT 14, 2019
Cancer
OCT 14, 2019
Understanding aging: new research
We all do it every day, but there’s still so much we don’t understand about it. I’m talking about aging. But now new research published r...
OCT 14, 2019
Cancer
OCT 14, 2019
New research targets pancreatic cancer tumors' environment
New research published in the journal Nature Communications highlights the inner workings of how pancreatic cancer cells spread. Pancreatic cancer is one o...
OCT 14, 2019
Cancer
OCT 14, 2019
Treating dogs with human breast cancer drugs
Did you know that dogs get lung cancer? New research published recently in the journal Clinical Cancer Research shows how dogs with cancer are benefiting f...
Loading Comments...